Regenerative Medicine


CellR4 2022; 10: e3332
DOI: 10.32113/cellr4_202210_3332

Safety study of cultured human Wharton’s Jelly mesenchymal stem cell therapy for multiple indications – a retrospective descriptive study

CellR4 2021; 9: e3130
DOI: 10.32113/cellr4_20214_3130

Autologous Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for treatment of patients with Fontaine stages III-IV peripheral arterial disease: a pilot safety and feasibility study

CellR4 2021; 9: e3132
DOI: 10.32113/cellr4_20214_3132

Safety and efficacy of systemically administered autologous Gold-Induced Cytokines (GOLDIC®)

CellR4 2021; 9: e3060
DOI: 10.32113/cellr4_20212_3060

Adipose-derived Stromal Vascular Matrix (SVM): a new paradigm in regenerative medicine

CellR4 2020; 8: e2873
DOI: 10.32113/cellr4_20207_2873

Hyperconcentrated Platelet-Rich Plasma (High-PRP) for the treatment of a non-healing ulcer of the lateral malleolus: a case report and literature review

CellR4 2017; 5 (3): e2404

Treatment of late sequelae of burn scar fibrosis with adipose-derived stromal vascular fraction (SVF) cells

CellR4 2016; 4 (5): e2134

Clinical trials of mesenchymal stem cell transplantation in patients with type 1 diabetes and systemic lupus erythematosus: is it time for larger studies?

CellR4 2016; 4 (3): e2084

Autologous dermal fibroblasts for the correction of age-related skin changes (SPRS-therapy®). Results of 2-year clinical trials and post-marketing clinical studies